Infographic
Oncology infographic: data normalization pathways
Date Published:
Register to DownloadAbout this Infographic
According to consensus recommendations, variability between operators remains a key limitation, as discussed in the accompanying commentary. In routine practice, cost considerations continue to shape adoption in smaller units, as discussed in the accompanying commentary. Recent studies suggest that cross-disciplinary review changes the initial assessment in a sizeable minority of cases, which has direct implications for daily practice.
Longitudinal data show that patient selection criteria deserve closer scrutiny, although confirmatory data are still limited. Longitudinal data show that real-world registries complement randomized trial evidence, a finding echoed by several independent groups. Longitudinal data show that real-world registries complement randomized trial evidence, with meaningful differences between subgroups. In multidisciplinary settings, threshold harmonization is still an open question, as discussed in the accompanying commentary. Contrary to earlier assumptions, early intervention correlates with better long-term outcomes, particularly in resource-constrained settings.
Across multiple cohorts, pre-analytical factors account for a large share of observed variance, a finding echoed by several independent groups. According to consensus recommendations, pre-analytical factors account for a large share of observed variance, and this trend is expected to continue. In multidisciplinary settings, training and accreditation are decisive for reproducibility, as discussed in the accompanying commentary. Longitudinal data show that standardized reporting improves comparability between centers, a finding echoed by several independent groups. According to consensus recommendations, real-world registries complement randomized trial evidence, a finding echoed by several independent groups.
In routine practice, variability between operators remains a key limitation, which has direct implications for daily practice. Contrary to earlier assumptions, cost considerations continue to shape adoption in smaller units, and this trend is expected to continue. Recent studies suggest that integrating quantitative measures reduces subjective bias, although confirmatory data are still limited. Across multiple cohorts, digital tooling shortens time-to-decision considerably, although confirmatory data are still limited. When protocols are compared, standardized reporting improves comparability between centers, and this trend is expected to continue.
Across multiple cohorts, digital tooling shortens time-to-decision considerably, and this trend is expected to continue. Across multiple cohorts, early intervention correlates with better long-term outcomes, and this trend is expected to continue.
References
- Haddad et al. Biomarker-guided therapy. J Oncology Res. 2026;24(6):612-1094.
- Haddad et al. Patient-reported outcomes. J Oncology Res. 2026;24(9):720-1031.
- Novak et al. Early screening programs. J Oncology Res. 2025;35(12):654-1055.